GLYX-13 117928-94-6 CAS NO.117928-94-6

GLYX-13 is a partial agonist of the NMDA recept- specifically at the glycine binding site. It has been shown to enhance memory learning in both young adult learning-impaired, aging rat models. GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier has been shown to increase Schaffer collateral-CA1 LTP in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, dentate gyrus pyramidal neurons under glucose oxygen-deprived conditions. Preclinical data indicates that GLYX-13 has a therapeutic index of 500 more, onset within 20 minutes of administration, produces antidepressant-like effects lasting approximately two weeks following administration. Currently under development by Naurex Inc, the compound recently completed phase II trials as a treatment fthose resistant non-responsive to traditional antidepressants.

GLYX-13 is a partial agonist of the NMDA recept- specifically at the glycine binding site. It has been shown to enhance memory learning in both young adult learning-impaired, aging rat models. GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier has been shown to increase Schaffer collateral-CA1 LTP in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, dentate gyrus pyramidal neurons under glucose oxygen-deprived conditions. Preclinical data indicates that GLYX-13 has a therapeutic index of 500 more, onset within 20 minutes of administration, produces antidepressant-like effects lasting approximately two weeks following administration. Currently under development by Naurex Inc, the compound recently completed phase II trials as a treatment fthose resistant non-responsive to traditional antidepressants.